Ibandronate sodium (Ibandronic acid monosodium salt, Bondronat)is a potent bisphosphonate drug and bone resorption inhibitor for the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in the people with cancer. It has been investigated for in vitro anti-tumor effects, such as apoptosis induction, inhibitor of cell growth, inhibition of invasive behavior, and inhibition of angiogenesis and for its in vivo role in various cancers including breast and prostate cancers.
Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras.
Etidronate (EHDP) Inhibits Osteoclastic-Bone Resorption, Promotes Apoptosis and Disrupts Actin Rings in Isolate-Mature Osteoclasts.
Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates.
Bisphosphonates Inhibit Angiogenesis in Vitro and Testosterone-stimulated Vascular Regrowth in the Ventral Prostate in Castrated Rats.
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
 S.P.Luckman, et al, J. Bone Miner. Res., 1998, 13(4), pp 581-589.